It is possible that the improved adjuvant options such as use of aromatase inhibitors in BRCA2 carriers, who have predominantly suffered from ER-positive breast cancers, could have equalised the effect of higher risk of ovarian cancer in BRCA1 carriers. Here, BRCA1 is linked to ovarian carcinoma.